Kiniksa Pharmaceuticals International Insider Sold Shares Worth $370,475, According to a Recent SEC Filing

MT Newswires16:48 ET

Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $34

Moomoo NewsApr 17 02:32 ET · Ratings

Express News | Wedbush Reiterates Outperform on Kiniksa Pharmaceuticals, Maintains $34 Price Target

BenzingaApr 16 10:06 ET

Evercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)

TipRanksApr 15 03:16 ET · Ratings

AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."

① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.

cls.cnApr 11 07:59 ET

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsApr 11 02:32 ET · Ratings